BioNTech Announces Corporate Form Transition from AG to SE; Welcomes Ryan Richardson as Senior Vice President Corporate Development and Strategy and Appoints Dr. Ulrich Wandschneider as Member of Supervisory Board Read more about BioNTech Announces Corporate Form Transition from AG to SE; Welcomes Ryan Richardson as Senior Vice President Corporate Development and Strategy and Appoints Dr. Ulrich Wandschneider as Member of Supervisory Board
BioNTech erwirbt Antikörperproduktionsgeschäft von MAB Discovery Read more about BioNTech erwirbt Antikörperproduktionsgeschäft von MAB Discovery
BioNTech Acquires MabVax Therapeutics’ Antibody Assets to Expand Portfolio Read more about BioNTech Acquires MabVax Therapeutics’ Antibody Assets to Expand Portfolio
BioNTech and Genmab Initiate First-In-Human Phase I/IIa Trial of Bispecific Antibody DuoBody®-PD-L1x4-1BB in Solid Tumors Read more about BioNTech and Genmab Initiate First-In-Human Phase I/IIa Trial of Bispecific Antibody DuoBody®-PD-L1x4-1BB in Solid Tumors
BioNTech Raises USD 325 Million in an Upsized Series B Financing to Further Advance Individualized Immuno-Oncology Pipeline Read more about BioNTech Raises USD 325 Million in an Upsized Series B Financing to Further Advance Individualized Immuno-Oncology Pipeline
BioNTech Announces New Collaboration to Develop HIV and Tuberculosis Programs Read more about BioNTech Announces New Collaboration to Develop HIV and Tuberculosis Programs
BioNTech Announces Commencement of Initial Public Offering Read more about BioNTech Announces Commencement of Initial Public Offering
BioNTech Announces Pricing of Initial Public Offering Read more about BioNTech Announces Pricing of Initial Public Offering
